Suppr超能文献

多发性硬化症患者脑脊液中的tau蛋白、磷酸化tau蛋白和β-淀粉样蛋白42

Tau protein, phosphorylated tau protein and beta-amyloid42 in the cerebrospinal fluid of multiple sclerosis patients.

作者信息

Valis Martin, Talab Radomir, Stourac Pavel, Andrys Ctirad, Masopust Jirí

机构信息

Department of Neurology, Medical Faculty, Charles University and Teaching Hospital in Hradec Králové, Czech Republic.

出版信息

Neuro Endocrinol Lett. 2008 Dec;29(6):971-6.

Abstract

OBJECTIVES

The presented study focuses on the importance of measurement of beta-amyloid42 (Abeta-42) levels, total tau protein, and phosphorylated tau (p-tau) protein in the cerebrospinal fluid (CSF) of cerebrospinal multiple sclerosis (MS) and clinically isolated syndrome (CIS) which represents an early phase of multiple sclerosis.

METHODS

A total of 23 patients with clinically isolated syndrome and suspected MS were enrolled into the study. Of this number, 14 patients met the criteria for definitive MS according to McDonald. The control group consisted of 40 patients examined for the possibility of organic damage to the brain, which was not confirmed. We used method of enzyme immunoanalysis to examine concentrations of tau protein, p- tau protein, and beta amyloid42. Differences between the respective groups were examined by test statistics. In addition, dependence of the total tau protein, p-tau protein, and beta-amyloid42 levels on demographic variables, diagnosis and duration of disease was examined by correlation analysis. Correlation of the concentrations obtained in the measurements was evaluated based on the calculated correlation coefficient (r) and level of significance (p).

RESULTS

Compared to the control group, no statistically significant difference was found in the levels of tau protein and p-tau protein between the CIS group and definitive MS group. A significant increase was found only for beta-amyloid42 levels in patients with diagnosed MS vs. control group. We demonstrated no correlation between the beta-amyloid42 and tau protein levels, p-tau protein and age of patients and duration of disease in patients with MS, CIS and the control group.

CONCLUSION

Results of our study show that use of tau protein, p-tau protein and beta-amyloid42 in the diagnosis of multiple sclerosis seems to be non-beneficial. We confirmed no importance for the differential diagnosis of an early stage MS.

摘要

目的

本研究聚焦于测量脑脊液(CSF)中β-淀粉样蛋白42(Aβ-42)水平、总tau蛋白和磷酸化tau(p-tau)蛋白在多发性硬化症(MS)和临床孤立综合征(CIS,代表多发性硬化症的早期阶段)中的重要性。

方法

共有23例临床孤立综合征且疑似MS的患者纳入本研究。其中,14例患者根据麦克唐纳标准符合确诊MS的标准。对照组由40例接受脑部器质性损伤可能性检查但未得到证实的患者组成。我们采用酶免疫分析方法检测tau蛋白、p-tau蛋白和β-淀粉样蛋白42的浓度。通过检验统计量检查各相应组之间的差异。此外,通过相关分析检查总tau蛋白、p-tau蛋白和β-淀粉样蛋白42水平与人口统计学变量、诊断及病程的相关性。根据计算出的相关系数(r)和显著性水平(p)评估测量中获得的浓度之间的相关性。

结果

与对照组相比,CIS组和确诊MS组之间的tau蛋白和p-tau蛋白水平未发现有统计学意义的差异。仅在确诊MS的患者与对照组之间发现β-淀粉样蛋白42水平有显著升高。我们证明在MS、CIS和对照组患者中,β-淀粉样蛋白42与tau蛋白水平、p-tau蛋白与患者年龄及病程之间无相关性。

结论

我们的研究结果表明,使用tau蛋白、p-tau蛋白和β-淀粉样蛋白42进行多发性硬化症的诊断似乎并无益处。我们证实其对早期MS的鉴别诊断无重要意义。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验